Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

The stock carries a hefty premium, but it is justified by the company's growth and the size of the market for GLP-1s. Eli Lilly's Q1 report ... maintaining its revenue forecast of $58 billion ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The company missed its earnings per share (EPS) forecast, reporting $3.34 against an expected $3.46. The market reacted negatively, with Eli Lilly’s stock dropping 8.56% in pre-market trading.

Investors are buying Hims & Hers Health ( HIMS 10.09%) stock hand over fist after the mail-order drugs company reported an earnings miss but a sales beat last night. But they're selling off shares of ...

However, this forecast, 3% lower for revenue and ... investors should hold on buying more NVO stock, as it appears that Eli Lilly’s research expenses are to pay off even more in the obesity ...

While maintaining its revenue forecast ... Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 drugs ...